Studies showing meaningful GLP-1 responses from amino acid stimulation often use higher doses or more targeted delivery methods
Hypoglycemia : Blood sugar that is too low (typically below 70 mg/dL), which can be a risk if GLP-1 RAs are taken with other diabetes medications like insulin (7) Overview Baseline parameters (8) Patient parameters for use include the following: Confirmation of Type 2 diabetes Baseline HgbA1C of 8% or higher responds well to medication
As an investigational research peptide, BPC-157 is widely studied in laboratory environments for its interactions with cellular signaling pathways involved in angiogenesis, extracellular matrix remodeling, inflammatory responses, endothelial biology, and tissue repair mechanisms
Of the 1822 participants on a GLP-1 RA, 72% (1309 individuals) were still on therapy for at least 3 years
What we like about a two product, targeted approach is that it attempts to address both directions of the GLP-1 pathway: Direct activation of L cells and receptor signalling Indirect support through the gut microbiome and metabolic environment That means we are not just telling the body to release more GLP-1, but also creating the conditions for GLP-1 to be more effective and longer lasting
Patients with HS can also have health problems like diabetes, high blood pressure, polycystic ovarian syndrome (PCOS), anxiety, depression, and irritable bowel syndrome (IBS)